Latency after preterm prelabor rupture of the membranes: increased risk for periventricular leukomalacia by Denzler, Annick et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
Latency after preterm prelabor rupture of the membranes: increased risk for
periventricular leukomalacia
Denzler, Annick; Burkhardt, Tilo; Natalucci, Giancarlo; Zimmermann, Roland
Abstract: OBJECTIVE To identify the risk factors for cystic periventricular leukomalacia (cPVL) and
their implications for deciding between immediate delivery and conservative management of preterm
prelabor rupture of the membranes (pPROM). METHODS The following risk factors were compared be-
tween cPVL infants and 6440 controls: chorioamnionitis, sex, gestational age (GA), birth weight, pPROM,
and pPROM-delivery interval. Factor impact on cPVL risk and clinical decision-making was determined
by multivariate logistic regression. RESULTS Overall cPVL prevalence (n = 32) was 0.99/1000 births.
All cPVL infants but one were born <34 weeks of gestation and were <2500 g; 56% had histological
chorioamnionitis versus 1.1% of controls (OR 35.9; 95%-CI 12.6-102.7). Because chorioamnionitis is a
postnatal diagnosis, logistic regression was performed with prenatally available factors: pPROM-delivery
interval >48 hours (OR 9.0; 95%-CI 4.1-20.0), male gender (OR 3.2; 95%-CI 1.4-7.3). GA was not a
risk factor if birth weight was included. Risk decreased with increasing fetal weight despite a prolonged
pPROM-delivery interval. CONCLUSION pPROM-delivery interval is the single most important prena-
tally available risk factor for the development of cPVL. Immediate delivery favors babies with chorioam-
nionitis but disfavors those with non infectious pPROM. In the absence of clinical chorioamnionitis fetal
weight gain may offset the inflammatory risk of cPVL caused by a prolonged pPROM-delivery interval.
DOI: 10.1155/2014/874984
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-99476
Published Version
Originally published at:
Denzler, Annick; Burkhardt, Tilo; Natalucci, Giancarlo; Zimmermann, Roland (2014). Latency after
preterm prelabor rupture of the membranes: increased risk for periventricular leukomalacia. Journal of
Pregnancy, 2014(874984):online. DOI: 10.1155/2014/874984
Research Article
Latency after Preterm Prelabor Rupture of the Membranes:
Increased Risk for Periventricular Leukomalacia
Annick Denzler,1 Tilo Burkhardt,1 Giancarlo Natalucci,2 and Roland Zimmermann1
1 Department of Obstetrics, Zurich University Hospital, Frauenklinikstraße 10, 8091 Zurich, Switzerland
2Department of Neonatology, Zurich University Hospital, Frauenklinikstraße 10, 8091 Zurich, Switzerland
Correspondence should be addressed to Tilo Burkhardt; tilo.burkhardt@usz.ch
Received 5 March 2014; Revised 3 June 2014; Accepted 21 June 2014; Published 17 July 2014
Academic Editor: Rosa Corcoy
Copyright © 2014 Annick Denzler et al.This is an open access article distributed under the Creative CommonsAttribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. To identify the risk factors for cystic periventricular leukomalacia (cPVL) and their implications for deciding between
immediate delivery and conservative management of preterm prelabor rupture of the membranes (pPROM). Methods. The
following risk factors were compared between cPVL infants and 6440 controls: chorioamnionitis, sex, gestational age (GA), birth
weight, pPROM, and pPROM-delivery interval. Factor impact on cPVL risk and clinical decision-making was determined by
multivariate logistic regression. Results. Overall cPVL prevalence (𝑛 = 32) was 0.99/1000 births. All cPVL infants but one were
born <34 weeks of gestation and were <2500 g; 56% had histological chorioamnionitis versus 1.1% of controls (OR 35.9; 95%-
CI 12.6–102.7). Because chorioamnionitis is a postnatal diagnosis, logistic regression was performed with prenatally available
factors: pPROM-delivery interval >48 hours (OR 9.0; 95%-CI 4.1–20.0), male gender (OR 3.2; 95%-CI 1.4–7.3). GA was not a risk
factor if birth weight was included. Risk decreased with increasing fetal weight despite a prolonged pPROM-delivery interval.
Conclusion. pPROM-delivery interval is the single most important prenatally available risk factor for the development of cPVL.
Immediate delivery favors babies with chorioamnionitis but disfavors those with non infectious pPROM. In the absence of clinical
chorioamnionitis fetal weight gain may offset the inflammatory risk of cPVL caused by a prolonged pPROM-delivery interval.
1. Introduction
Cerebral palsy includes a group of nonprogressive movement
disorders due to brain lesions or abnormalities in early devel-
opment [1]. Its prevalence of 2 per 1000 newborns overall
rises to 77 per 1000 preterms born at below 28 0/7 weeks
of gestation [2, 3]. A major cause is cystic periventricular
leukomalacia (cPVL) comprising necrosis and subsequent
cyst formation of the periventricular white matter: 60–100%
of childrenwith cPVL develop cerebral palsy [4–6]. Although
the etiology and pathogenesis of cPVL remain unelucidated,
several perinatal risk factors appear involved [7]. Birth
asphyxia is no longer assumed the principal culprit [8].
Chorioamnionitis is thought to provoke a fetal inflam-
matory response syndrome associated with increased fetal
cytokines that may lead to neonatal brain injury. Several
studies indicate that the cytokines can themselves damage
white matter without bacteremia being required [8–15]. An
important predictor of chorioamnionitis is preterm prelabor
rupture of membranes (pPROM) [16]. One-third of women
with pPROM have positive amniotic fluid cultures [17].
Chorioamnionitis is quite common and often subclinical:
fever and inflammatory marker elevation are rare in the early
stages, making diagnosis difficult. Against this background
the optimal management of pPROM remains unknown. The
risks of prematurity from immediate delivery have to be bal-
anced against those of ascending intrauterine infection and
its probable consequences. Moreover subclinical chorioam-
nionitis is believed to cause pPROM. At a gestational age
below 34 0/7 weeks, half the gynecologists in Australia and
New Zealand preferred to induce labor, while the other
half chose conservative management [18]. Several studies
recommend an active management after 30 weeks [19, 20].
A Cochrane review from 2010 found no evidence about
which strategy is favorable [21]. Despite a lack of randomized
studies [22] new British and German guidelines advise
active management before 34 weeks and active management
between 34 and 36 weeks. Zurich University Hospital has
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hitherto favored conservativemanagement, delaying delivery
until clinically mandatory, on the grounds that the higher
mortality and morbidity of newborns at lower gestational
age are proven whereas the effect of increasing cPVL risk by
prolonging pregnancy remains unknown. Only a prospective
randomized trial can provide a definite answer. The more
limited objectives of the present studywere to identify the risk
factors for PVL in the conservative pPROMmanagement set-
ting and determine whether prolonging gestation outweighs
the risk of cPVL due to chorioamnionitis.
2. Materials and Methods
The study population comprised all babies with cPVL born
in Zurich University Hospital’s obstetric department between
1993 and 2008. Cranial ultrasound was obtained in infants
with gestational age below 32 0/7 weeks or birth weight below
1500 g at days 1, 3, and 7 of life and repeated weekly until
hospital discharge. cPVL was defined according to de Vries
et al. [23]. All 6440 infants born between 2005 and 2007 and
not affected by PVL served as controls.
During the study period women with premature con-
tractions received tocolytic drugs (hexoprenaline only until
2001, nifedipine or hexoprenaline from 2002 to 2008) for 48
hours to allow lungmaturationwith 24mg of betamethasone.
Urinary tract infection or bacterial vaginosis was treated
with antibiotics (co-amoxiclav or clindamycin). Steroids were
repeated every 10 days until 2002. Since then, all women
with threatened preterm delivery have received a single
course of steroids. Tocolysis was maintained thereafter if
contractions recurred after stopping tocolysis. Management
of pPROM pregnancy was largely consistent with British
Greentop Guideline no. 44 [17]. After pPROM co-amoxiclav
was used until 2001 when it was changed to erythromycin
[24], chorioamnionitis was monitored using blood tests
(including leukocytes andC-reactive protein (CRP) 12 hourly
for the first 48 hours ), maternal temperature, and fetal
heart rate. Clinical chorioamnionitis (≥ 3 of following
markers: leukocytes > 20,000/𝜇L, CRP > 40mg/dL, maternal
temperature > 38∘C, maternal tachycardia > 100 bpm, and
fetal tachycardia > 160 bpm) was treated with antibiotics (co-
amoxiclav) and prompt delivery. If the diagnosis was uncer-
tain, delivery was deferred until chorioamnionitis became
clinically obvious or delivery could be delayed no longer for
other reasons. Diagnosis was based on placental histology,
positive amniotic fluid cultures sampled at cesarean section,
or clinical parameters.
Babies born below 25 0/7 weeks were excluded in both
groups because inmost instances neonatal care was restricted
to comfort care. Infants with cPVL were monitored for long-
term follow-up. Neurodevelopmental disability was classified
according to Palisano et al. [25]. The risk factors recorded
in both groups were chorioamnionitis, pPROM-delivery
interval, gestational age at delivery, birth weight, gender, race,
and parity.
All statistical analyses were performed with STATA 10
Statistics/Data Analysis Software (Stata Corporation, College
Station, TX) using Pearson’s 𝜒2 test for comparisons of
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Figure 1: Exponential decrease in periventricular leukomalacia risk
with increasing birth weight.
frequencies and Wilcoxon’s rank-sum test for group com-
parisons. Odds ratios (OR) with 95% confidence intervals
(CI) were calculated. Subsequent to univariate analysis,
multivariate logistic regression was performed to test the
impact of factors such as chorioamnionitis, gestational age,
birth weight, gender, and pPROM-delivery interval on the
incidence of cPVL.The results were used to calculate the risks
of developing cPVL at different fetal weights and pPROM-
delivery intervals.
Given that the analysis was of anonymized data, the study
was exempt from local institutional review board approval.
Follow-up data of study preterms below 32 0/7 weeks were
extracted from the prospective national database of the
Swiss Neonatal Network & Follow-up Group. According to
the recommendations of our Research Ethics Committee
the investigators were obliged to inform parents about the
scientific use of anonymized data. Parents had the right to
refuse participation of their child.
3. Results
Between 1993 and 2008, 32,276 infants were born at Zurich
University Hospital, including 6027 (18.7%) preterms (below
37 0/7 weeks); over the same period 32 cases of cPVL
were recorded, representing an overall prevalence of 0.99‰
(Tables 1 and 2).
cPVL prevalence among preterm infants was 5.3‰. All
32 infants with PVL were delivered preterm and all but
one before 34 0/7 weeks. cPVL risk decreased exponentially
with increasing birth weight (Figure 1) and increasing ges-
tational age. Males were 3 times more affected than females
(male : female ratio 24 : 8). All birth weights in newborns with
cPVLwere less than 2500 g (Table 1).The individual pPROM-
delivery intervals of all PVL cases are shown in Figure 2.
Median infant age at cPVL diagnosis was 19 days (3–40
days). Of the 32 infants, five (16%) died within the first 6
weeks after birth. Of the 27 surviving infants, three (11%)
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Table 1: Baseline cystic periventricular leukomalacia (cPVL) and control group characteristics.
Characteristic cPVL (𝑛 = 32) Controls (𝑛 = 6,440) 𝑃
Gestational age (d) 207.5 (184–255) 273 (168–297) <0.001
Below 34 gestational weeks (%) 97 9 <0.001
Multiparous (𝑛 [%]) 12 (38) 3145 (49) 0.198
Birth weight (g, median [range]) 1197.5 (740–2250) 3270 (300–5700) <0.001
PROM (𝑛 [%]) 18 (56) 714 (11) <0.001
pPROM-delivery interval (h, median [range]) 38 (0–960) 1.3 (0–2170) 0.004
Chorioamnionitis (𝑛 [%]) 18 (56) 73 (1) <0.001
Lung maturation administration (𝑛 [%]) 27 (84) 281 (5) <0.001
Infant sex (𝑛 [%])
Female 8 (25) 3049 (47) 0.012
Male 24 (75) 3390 (53)
PROM: premature rupture of the membranes; pPROM: preterm premature rupture of the membranes.
Table 2: Characteristics and management of the cystic periventricular leukomalacia (cPVL) group (𝑛 = 32) by study period.
Characteristic Time period Time period Overall
1993–2001 2002–2008 1993–2008
Chorioamnionitis
Yes 12 (60) 6 (50) 18 (56)
No 6 (30) 6 (50) 12 (38)
Unknown 2 (10) 0 (0) 2 (6)
Premature rupture of membranes
Yes 11 (55) 7 (58) 18 (56)
No 9 (45) 5 (42) 14 (44)
Antenatal betamethasone
Yes 15 (75) 12 (100) 27 (84)
No 5 (25) 0 (0) 5 (16)
Infant sex
Male 15 (75) 9 (75) 24 (75)
Female 5 (25) 3 (25) 8 (25)
Total 20 (1.3‰) 12 (0.7‰) 32 (0.95‰)
Data are 𝑛 (%).
were lost to follow-up (parental refusal), while 24 (89%)
were neurodevelopmentally assessed at a median (range)
age of 3.8 years (2.0–10.2 years): one (4%) was normal,
nine (38%) were moderately disabled, defined as cerebral
palsy grade <3 according to the Gross Motor Function
Classification System (GMFCS), or cognitive impairment
with developmental quotient 55–69, or moderate visual or
hearing impairment, and 14/24 (54%) were severely disabled,
defined as disabling cerebral palsy (grade 3–5 GMFCS), or
severe cognitive disability with developmental quotient <55,
or major visual or hearing impairment.
Histologically confirmed chorioamnionitis was present
in 16 cPVL infants (50%). A further two infants, for
whom placental histology was missing, had ≥3 mark-
ers of clinical chorioamnionitis: leukocytes > 20,000/𝜇L,
CRP > 40mg/dL, maternal temperature > 38∘C, maternal
tachycardia > 100 bpm, and fetal tachycardia > 160 bpm.
Thus, 18/32 cases (56%) were classified as having been
complicated by chorioamnionitis. Two cases were assigned
to the nonchorioamnionitis group despite the absence
of placental histology and a number of clinical parame-
ters.
The control group included 134 cases of suspected
chorioamnionitis. Review of the placental histology and
clinical parameters reduced these to 71 cases of histological
chorioamnionitis and two cases of clinical chorioamnionitis
in the absence of placental histology. Chorioamnionitis thus
complicated 73/6440 (1.1%) of control deliveries.
Preliminary logistic regression revealed significant asso-
ciations between cPVL and chorioamnionitis, male sex, and
birth weight. Chorioamnionitis had the highest impact on
cPVL risk (OR 35.9, 95% CI 12.6–102.7). However, because a
prenatal diagnosis of chorioamnionitis is often not possible,
logistic regression was performed, replacing chorioamnioni-
tis by the pPROM-delivery interval. This revealed significant
impacts on cPVL by sex (𝑃 = 0.008), pPROM-delivery
interval > 48 hours (𝑃 < 0.001), and fetal weight (𝑃 < 0.001;
Table 3).
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Table 3: Multivariate logistic regression analysis of the influence of
fetal sex, preterm premature rupture of the membranes- (pPROM-)
delivery interval, and birth weight on cystic periventricular leuko-
malacia (cPVL) prevalence.
Covariate cPVL 𝑃
Sex
Female∗ 1
Male 3.1 (1.3–7.1) 0.008
pPROM-delivery interval
≤48 h∗ 1
>48 h 8.2 (3.8–17.5) <0.001
Per 100 g higher fetal weight 0.85 (0.81–0.89) <0.001
Data are adjusted odds ratios (95% confidence intervals).
∗Baseline category.
Table 4: Regression analysis of the impact of different birth weights
and preterm premature rupture of membranes- (pPROM-) delivery
intervals on periventricular leukomalacia risk, assuming fetal weight
gains of 0 g in 24 h and 48 h, 200 g in 1 week, and 400 g in 2 weeks
[26]. Data are estimated incidence of periventricular leukomalacia.
(a) Male infants
Birth weight
500 g 1000 g 1500 g 2000 g 2500 g
pPROM-delivery interval
0 h 0.268 0.096 0.035 0.012 0.004
24 h 0.279 0.100 0.036 0.013 0.005
48 h 0.291 0.105 0.038 0.014 0.005
1 week 0.240 0.086 0.031 0.012 0.004
2 weeks 0.214 0.077 0.028 0.010 0.004
(b) Female infants
Birth weight
500 g 1000 g 1500 g 2000 g 2500 g
pPROM-delivery interval
0 h 0.081 0.029 0.010 0.004 0.001
24 h 0.085 0.030 0.011 0.004 0.001
48 h 0.088 0.032 0.011 0.004 0.001
1 week 0.073 0.026 0.009 0.003 0.001
2 weeks 0.065 0.023 0.008 0.003 0.001
Further multiple logistic regression analyses revealed sig-
nificant associations between chorioamnionitis and pPROM-
delivery interval > 24 hours (𝑃 = 0.002) and gestational age
(𝑃 < 0.001). No significant influence of ethnicity (𝑃 = 0.49),
fetal weight (𝑃 = 0.37), or parity (𝑃 = 0.79) was observed.
According to logistic regression analyses tabulation of
estimated cPVL incidence at varying pPROM-delivery inter-
vals and birth weights for boys and girls (Table 4), assuming
fetal weight gain of 200 g/week [26], revealed a slight rise
in the first 48 hours, followed by a significantly lower risk
after the first and second week of prolongation of preg-
nancy. Increasing fetal weight during pPROM latency had
a far stronger protective effect despite a prolonged pPROM-
delivery interval being a risk factor for cPVL.
4. Discussion
Zurich University Hospital’s obstetrics department is a ter-
tiary referral center. This accounts for the high prevalence
of preterm deliveries compared to the national average (19%
versus 9%) [27]. The prevalence of cPVL in our study group
(0.99‰) appears lower than the few reports in the literature.
Hamrick et al. reported an incidence of 1.8% at UC San
Francisco in 1992, falling to 0.2% in 2002; the incidence of
cPVL in children weighing <1500 g decreased from 2.9% to
0.5% over the same period [28].
The difference may be partly due to Zurich’s conservative
management of newborns below 25 0/7 weeks of gesta-
tion (restriction to comfort care in the majority of cases)
[29]. We may also have missed some cases of late cPVL
diagnosis in children born after 32 0/7 weeks (there were
no instances of late diagnosis of brain lesions in preterms
included in long-term follow-up). Given our small sample
size, we could only extrapolate cPVL incidence for birth
weights <1000 g (Figure 1). The Vermont Oxford Network
reported approximately 3% cPVL at birth weights 751–1500 g;
risk was highest (6%) at birth weights <751 g [30]. Our data
confirm the reported exponential decrease in cPVL incidence
with increasing birth weight [28, 30]. They also confirm a
similar exponential decrease with advancing gestational age
independently of birth weight [30]. Again, our data at below
26 0/7 weeks are not comparable to other centers due to our
conservative management of newborns around 25 0/7 weeks.
Our data support the dependency of cPVL risk on the
pPROM-delivery interval [8, 31], but not on either low parity
or PROM [8, 10, 31]. The finding of a 4 : 1 male/female ratio
confirms previous reports [8, 15, 31] but remains uneluci-
dated.
We also confirmed the several reports of a significant
association between cPVL and chorioamnionitis [8, 9, 11, 14,
15]. The fact that only one cPVL baby had a positive blood
culture within 3 days of birth supports the hypothesis that
fetal inflammatory response syndrome is perfectly capable of
causing brain damage even in the absence of bacteremia [32–
34]. Apart from being a risk factor for cPVL, chorioamnioni-
tis is well-recognized as correlating with neonatal morbidity
and mortality [32–34].
Unfortunately, these risk factors cannot resolve our
strategic dilemma of immediate versus delayed delivery
for lowering short-term mortality and long-term sequelae.
Chorioamnionitis is a major complication of pPROM but
probably even more often the cause of pPROM.
The increase in cPVL risk during the first 48 hours after
pPROM and the substantial decrease thereafter at varying
birth weights and pPROM-delivery intervals (Table 4) can be
interpreted in several ways. For example, the initial increase
may relate to the use of antenatal steroids to induce lung
maturation. Steroids could facilitate the spread of bacterial
infection; they could also modulate the fetal inflammatory
cytokines thought to cause brain damage [14]. Corroborative
evidence is that the incidence of cPVL in our group decreased
from 1.3‰ on repeated steroid courses to 0.7‰ on single-
course steroids (although we must admit to having concomi-
tantly switched to erythromycin and introduced nifedipine
Journal of Pregnancy 5
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Figure 2: Data from 32 cPVL cases in two time periods. Each bar
represents a pregnancy with pPROM-delivery interval beginning
with gestational age of pPROM.
tocolysis). This study could not add any information about
the impact of the different changed interventions to the lower
cPVL incidence 2002–2008.
Another explanation is that the inverted U-shaped risk
for cPVL with respect to the pPROM-delivery interval
results from superposing two distinct groups of women: one
with pPROM due to chorioamnionitis and the other with
pPROM from a noninfectious cause. Most chorioamniotic
pregnancieswill deliverwithin a fewdays after pPROM.Thus,
women still pregnant after one week of pPROM are more
likely to have a noninfectious cause of fluid leakage. As a
consequence, delaying delivery in these cases would lower
cPVL risk by allowing birth weight to increase. At the same
time, by increasing gestational age and birth weight, this
strategy would substantially decrease all other complications
of prematurity such as cerebral hemorrhage or lung pathol-
ogy [35]. Conversely, a conservative strategy would increase
cPVL risk in the infectious group. An increased risk for
neurodevelopmental impairment in the first 48 to 72 hours
after pPROMwas also observed in a large French cohort with
1884 infants born at 24–32 weeks of gestational age [36].
Given this strong association between cPVL and
chorioamnionitis, it is absolutely essential to diagnose
intrauterine infection as early as possible. This points once
again to the urgent need for a tool that reliably diagnoses
chorioamnionitis.
In the absence of such a tool, either strategy carries a
considerable risk of Pyrrhic victory. Because cPVL affects
only a small proportion of newborns, with other problems
of prematurity playing a much larger role, it seems not
unreasonable to pursue a conservative strategy until prospec-
tive randomized trials provide a definitive answer or, at the
least, until we have a reliable test for the early diagnosis of
chorioamnionitis. Perinatal morbidity is strongly correlated
with prematurity and latency does not appear to worsen
outcome in pPROM [37].
The fact that chorioamnionitis and the pPROM-delivery
interval seem to have a high impact on the risk of developing
cPVL in our study could have important consequences for the
future management of pPROM.
The strengths of this study are that all infants and
mothers were monitored in the same department and that all
preterms below 32 0/7 weeks received long-term follow-up,
where possible (the actual follow-up rate was 89%). Only in
midstudywere there any relevant changes in themanagement
of pPROM (antibiotics, tocolytic, and steroid courses).
The study’s limitations lie in its retrospective design and
small cPVL sample size.Wehadparticularly fewbirthweights
below 1000 g, partly because the Swiss Society ofNeonatology
recommends restricting neonatal management to comfort
care at gestational ages below 24 0/7 weeks. Between 24 0/7
and 25 6/7 weeks of gestation the decision to undertake
intensive care is individual and influenced by prenatal factors
such as birth weight, gender, antenatal steroid use, intrauter-
ine growth restriction, chorioamnionitis, fetal malformation,
multiple gestation, and clinical condition immediately after
delivery (asphyxia, heart rate, activity, and response to
initial resuscitation). Intervention continues in the neonatal
intensive care unit with the primary goal of survival with
an acceptable quality of life [29]. Our results are helpful for
deliveries between 26 and 34 weeks of gestation only.
Other factors accounting for small sample size in any
study of this kind include the fact that the true number of
newborns with cPVL can be difficult to evaluate due to early
postnatal death, especially when gestational age is very low.
cPVL can often only be diagnosed weeks after birth because
it takes time for the periventricular cysts to become visible
on ultrasound. Failure of underreporting when making a late
diagnosis of cPVL is another source.
Even if a prolonged pPROM-delivery interval may briefly
increase the risk of cPVL, we believe that conservative man-
agement makes sense in the absence of clinical chorioam-
nionitis. Higher infant weight at delivery compensates for the
impact of pPROM latency onneonatal outcomeprovided that
the pregnancy can be prolonged by more than 48 hours.
Conflict of Interests
The authors declare that they have no financial or nonfinan-
cial conflict of interests.
Authors’ Contribution
Annick Denzler and Tilo Burkhardt have made substantial
contributions to acquisition of obstetrical data and analysis
and interpretation of all data. Giancarlo Natalucci has sub-
stantial contributions to acquisition of neonatal and outcome
data. Roland Zimmermann conceived of the study and
participated in coordination and helped to draft the paper. All
authors read and approved the final paper. Annick Denzler
and Tilo Burkhardt contributed equally to the study and
paper.
References
[1] F. Stanley, E. Blair, and E. Alberman, “Pathways to cerebral palsy
involving very preterm birth,” in Cerebral Palsies Epidemiology
6 Journal of Pregnancy
& Causal Pathways, F. Stanley, E. Blair, and E. Alberman, Eds.,
pp. 60–82, Mac Keith Press, London, UK, 2000.
[2] K. Himmelmann, G. Hagberg, E. Beckung, B. Hagberg, and P.
Uvebrant, “The changing panorama of cerebral palsy in Sweden.
IX. Prevalence and origin in the birth-year period 1995–1998,”
Acta Paediatrica, vol. 94, no. 3, pp. 287–294, 2005.
[3] S. Winter, A. Autry, C. Boyle, and M. Yeargin-Allsopp, “Trends
in the prevalence of cerebral palsy in a population-based study,”
Pediatrics, vol. 110, no. 6, pp. 1220–1225, 2002.
[4] A. Leviton and N. Paneth, “White matter damage in preterm
newborns: an epidemiologic perspective,” Early Human Devel-
opment, vol. 24, no. 1, pp. 1–22, 1990.
[5] J. J. Volpe and A. Zipurksy, “Neurobiology of periventricular
leukomalacia in the premature infant,” Pediatric Research, vol.
50, no. 5, pp. 553–562, 2001.
[6] Y. Murata, A. Itakura, K. Matsuzawa, A. Okumura, K. Wakai,
and S. Mizutani, “Possible antenatal and perinatal related
factors in development of cystic periventricular leukomalacia,”
Brain & Development, vol. 27, no. 1, pp. 17–21, 2005.
[7] I. Blumenthal, “Periventricular leucomalacia: a review,” Euro-
pean Journal of Pediatrics, vol. 163, no. 8, pp. 435–442, 2004.
[8] M. M. Costantine, H. Y. How, K. Coppage, R. A. Maxwell, and
B. M. Sibai, “Does peripartum infection increase the incidence
of cerebral palsy in extremely low birthweight infants?” The
American Journal of Obstetrics and Gynecology, vol. 196, no. 5,
pp. e6–e8, 2007.
[9] R. Romero, J. Espinoza, L. F. Gonc¸alves, J. P. Kusanovic, L.
Friel, and S. Hassan, “The role of inflammation and infection
in preterm birth,” Seminars in Reproductive Medicine, vol. 25,
no. 1, pp. 21–39, 2007.
[10] Y. W. Wu, G. J. Escobar, J. K. Grether, L. A. Croen, J. D. Greene,
and T. B. Newman, “Chorioamnionitis and cerebral palsy in
term and near-term infants,” Journal of the American Medical
Association, vol. 290, no. 20, pp. 2677–2684, 2003.
[11] K. Tsukimori, H. Komatsu, T. Yoshimura et al., “Increased
inflammatory markers are associated with early periventricular
leukomalacia,” Developmental Medicine and Child Neurology,
vol. 49, no. 8, pp. 587–590, 2007.
[12] E.M.Graham,C. J.Holcroft,K.K. Rai, P. K.Donohue, andM.C.
Allen, “Neonatal cerebral whitematter injury in preterm infants
is associated with culture positive infections and only rarely
withmetabolic acidosis,”TheAmerican Journal of Obstetrics and
Gynecology, vol. 191, no. 4, pp. 1305–1310, 2004.
[13] A. Bashiri, E. Burstein, and M. Mazor, “Cerebral palsy and
fetal inflammatory response syndrome: a review,” Journal of
Perinatal Medicine, vol. 34, no. 1, pp. 5–12, 2006.
[14] G. Rocha, E. Proenc¸a, C. Quintas, T. Rodrigues, and H.
Guimar´ıes, “Chorioamnionitis and brain damage in the preterm
newborn,” Journal ofMaternal-Fetal andNeonatalMedicine, vol.
20, no. 10, pp. 745–749, 2007.
[15] E. Hatzidaki, E. Giahnakis, S. Maraka et al., “Risk factors for
periventricular leukomalacia,” Acta Obstetricia et Gynecologica
Scandinavica, vol. 88, no. 1, pp. 110–115, 2009.
[16] B. M. Mercer, “Preterm premature rupture of the membranes,”
Obstetrics and Gynecology, vol. 101, no. 1, pp. 178–193, 2003.
[17] RCOG, “Guideline No. 44: Preterm prelabour rupture of mem-
branes,” November 2006.
[18] S. Buchanan, C. Crowther, and J. Morris, “Preterm prelabour
rupture of the membranes: a survey of current practice,”
The Australian and New Zealand Journal of Obstetrics and
Gynaecology, vol. 44, no. 5, pp. 400–403, 2004.
[19] L. Hartling, R. Chari, C. Friesen, B. Vandermeer, and T. Lacaze-
Masmonteil, “A systematic review of intentional delivery in
women with preterm prelabor rupture of membranes,” Journal
of Maternal-Fetal and Neonatal Medicine, vol. 19, no. 3, pp. 177–
187, 2006.
[20] J. C. Pasquier, E. Bujold, M. Rabilloud et al., “Effect of latency
period after premature rupture of membranes on 2 years infant
mortality (DOMINOS study),” European Journal of Obstetrics
Gynecology and Reproductive Biology, vol. 135, no. 1, pp. 21–27,
2007.
[21] S. L. Buchanan, C. A. Crowther, K. M. Levett, P. Middleton, and
J. Morris, “Planned early birth versus expectant management
for womenwith preterm prelabour rupture of membranes prior
to 37 weeks’ gestation for improving pregnancy outcome,” The
Cochrane Database of Systematic Reviews, no. 3, Article ID
CD004735, 2010.
[22] AMWF-Leitlinien-Register: Empfehlungen zum Vorgehen bei
vorzeitigem Blasensprung, http://www.awmf.org/.
[23] L. S. de Vries, P. Eken, and L. M. S. Dubowitz, “The spectrum
of leukomalacia using cranial ultrasound,” Behavioural Brain
Research, vol. 49, no. 1, pp. 1–6, 1992.
[24] S. L. Kenyon, D. J. Taylor, and W. Tarnow-Mordi, “Broad-
spectrum antibiotics for preterm, prelabour rupture of fetal
membranes: the ORACLE I randomised trial,”The Lancet, vol.
357, no. 9261, pp. 979–988, 2001.
[25] R. Palisano, P. Rosenbaum, S. Walter, D. Russell, E. Wood,
and B. Galuppi, “Development and reliability of a system to
classify gross motor function in children with cerebral palsy,”
Developmental Medicine & Child Neurology, vol. 39, no. 4, pp.
214–223, 1997.
[26] G. M. Beutler, J. Kurmanaviclus, M. Hoffmann, E. Welzl, R.
Huch, andM. Bajka, “New nomogram for foetal weight estima-
tion based on Hadlock’s two-parameter formula,” Ultraschall in
der Medizin, vol. 25, no. 1, pp. 58–64, 2004.
[27] Bundesamt fu¨r Statistik (BFS), Neugeborene in Schweizer
Spita¨lern 2004, Stat Sante´, 2004.
[28] S. E. G. Hamrick, S. P. Miller, C. Leonard et al., “Trends
in severe brain injury and neurodevelopmental outcome in
premature newborn infants: the role of cystic periventricular
leukomalacia,” Journal of Pediatrics, vol. 145, no. 5, pp. 593–599,
2004.
[29] T. Berger, V. Bu¨ttiker, J. Fauche`re et al., “ecommendations for
the care of infants born at the limit of viability (gestational age
22-26 weeks),” in Swiss Society of Neonatology, 2002.
[30] Vermont Oxford Network, Vermont-Oxford Network Expanded
Database Summary, Burlington, Burlington, Vt, USA, 2006.
[31] M. Bauer, C. Fast, J. Haas, B. Resch,U. Lang, andB. Pertl, “Cystic
periventricular leukomalacia in preterm infants: an analysis of
obstetric risk factors,” Early Human Development, vol. 85, no. 3,
pp. 163–169, 2009.
[32] J. M. Zhang, F. T. Kraus, and T. I. Aquino, “Chorioamnionitis:
a comparative histologic, bacteriologic, and clinical study,”
International Journal of Gynecological Pathology, vol. 4, no. 1, pp.
1–10, 1985.
[33] J. V. Been, I. G. I. J. G. Rours, R. F. Kornelisse et al., “Histologic
chorioamnionitis, fetal involvement, and antenatal steroids:
effects on neonatal outcome in preterm infants,”The American
Journal of Obstetrics and Gynecology, vol. 201, no. 6, pp. 587.e1–
587.e8, 2009.
[34] A. Wolfensberger, R. Zimmermann, and U. Von Mandach,
“Neonatal mortality and morbidity after aggressive long-term
Journal of Pregnancy 7
tocolysis for preterm premature rupture of the membranes,”
Fetal Diagnosis and Therapy, vol. 21, no. 4, pp. 366–373, 2006.
[35] T. P. Waters and B. M. Mercer, “The management of preterm
premature rupture of the membranes near the limit of fetal
viability,” The American Journal of Obstetrics and Gynecology,
vol. 201, no. 3, pp. 230–240, 2009.
[36] T. Mura, J.-C. Picaud, B. Larroque et al., “Cognitive impairment
at age 5 years in very preterm infants born following premature
rupture of membranes,”The Journal of Pediatrics, vol. 163, no. 2,
pp. 435.e2–440.e2, 2013.
[37] T. A. Manuck, C. C. Maclean, R. M. Silver, and M. W. Varner,
“Preterm premature rupture of membranes: does the duration
of latency influence perinatal outcomes?” American Journal of
Obstetrics & Gynecology, vol. 201, no. 4, pp. 414.e1–414.e6, 2009.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
